RecruitingPhase 3NCT05835310
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy
Sponsor
AstraZeneca
Enrollment
100 participants
Start Date
Mar 14, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)
Eligibility
Min Age: 5 YearsMax Age: 17 Years
Inclusion Criteria6
- Participant's parent/caregiver/legally authorized representative and participant (if required per local country regulation) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Informed assent is to be provided by the participant per local country regulation.
- Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria for at least 3 months prior to signing the ICF.
- Participant should meet all of following tuberculosis (TB) criteria:
- A. No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit
- Female participants of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
- Female participants of childbearing and male participants must adhere to the contraception methods.
Exclusion Criteria11
- Known diagnosis of an IFN-mediated autoinflammatory interferonopathy.
- History of, or current diagnosis of, clinically significant non-SLE-related vasculitides.
- In participants aged 11 years and above: history or evidence of suicidal ideation.
- History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
- Any positive result on screening for human immunodeficiency virus.
- Active hepatitis B surface antigen OR hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any active or recent case of Herpes Zoster infection.
- Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.
- History of severe COVID-19 infection requiring hospitalization, intensive care unit care, or assisted ventilation or any prior COVID-19 infection with unresolved sequelae. Any mild/asymptomatic COVID-19 infection (laboratory confirmed or suspected based on clinical symptoms).
- Prior use of anifrolumab.
- Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg, rituximab) \< 26 weeks prior to ICF signature.
- Blood transfusion or receipt of blood products except albumin within 4 weeks prior to signing the ICF.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAnifrolumab
Participants will receive anifrolumab via IV infusion.
DRUGPlacebo
Participants will receive matching placebo via IV infusion
Locations(97)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05835310
Related Trials
Study of Systemic Lupus Erythematosus
NCT000013721 location
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
NCT048334651 location
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
NCT069843412 locations
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT054404221 location
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325219 locations